Drugs / LY2584702
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01372085 | Jun → Sep 2011 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01241461 | Nov 2010 → Nov 2011 | cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01115803 | Mar 2010 → Jun 2011 | metastatic neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, renal cell carcinoma | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1 | NCT01394003 | Nov 2008 → Apr 2011 | cancer of unknown primary site | Eli Lilly and Company | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2584702 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01241461 ↗ |
| Known as | LY2584702 tosylate | “BACKGROUND: LY2584702 tosylate (hereafter referred to as LY2584702) is a potent, highly selective adenosine triphosphate (ATP) competitive inhibitor against p70 S6 kinase, a...” PMID 24440085 ↗ Jan 20141“LY2584702 tosylate (hereafter referred to as LY2584702) is an oral, selective ATP competitive inhibitor of p70 S6 kinase.” PMID 24456794 ↗ Jan 2014 |
| Action | Inhibit | “selective ATP competitive inhibitor of p70 S6 kinase” PMID 24456794 ↗ Jan 20141“Ribosomal protein S6 kinase 1 inhibitor” CHEMBL3545076 ↗ |
| Modality | Small molecule | — CHEMBL3545076 ↗ |
| Route | Oral | “administered orally” NCT01115803 ↗ |
| Target | RPS6KB1 | “Ribosomal protein S6 kinase 1 inhibitor” CHEMBL3545076 ↗ |